Evercore ISI Adjusts GE Healthcare Technologies Price Target to $83 From $84, Maintains Outperform Rating

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

GE Vernova's shares fell 3.42% to $994 on October 7, despite securing a U.S. construction permit for its BWRX-300 small nuclear reactor. The permit, issued by TVA for the Clinch River project, is a regulatory milestone, but commercial success remains uncertain. GE Vernova aims to leverage repeat business from the design, but investors await funded projects and equipment orders to validate the opportunity.

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

GE HealthCare agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash, expanding its radiopharmaceutical supply chain. The deal, expected to close in H1 2027, includes 15 U.S. manufacturing sites and rights to FAPI-74. GE HealthCare anticipates revenue growth and margin expansion from the acquisition.

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

GE HealthCare (GEHC) has agreed to acquire SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, from Trilantic North America. The deal aims to expand GEHC's footprint in the PET radiopharmaceutical supply chain.